National Cancer Institute; Notice of Closed Meeting, 66733 [2011-27867]

Download as PDF Federal Register / Vol. 76, No. 208 / Thursday, October 27, 2011 / Notices Cancer Control, National Institutes of Health, HHS) Dated: October 21, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. Dated: October 21, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–27868 Filed 10–26–11; 8:45 am] BILLING CODE 4140–01–P [FR Doc. 2011–27867 Filed 10–26–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute; Notice of Closed Meeting National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c) (4) and 552b(c) (6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources, biologics, clinical assays and other developmental programs for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. wreier-aviles on DSK7SPTVN1PROD with NOTICES National Institutes of Health National Cancer Institute; Notice of Meetings Name of Committee: National Cancer Institute Special Emphasis Panel, Clinical Assay Development Program (CADP). Date: November 29, 2011. Time: 8 a.m.–3 p.m. Agenda: To review grant applications for the CADP. Place: Bethesda Marriott North Hotel, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Dr. Tracy Lively, Executive Secretary, Clinical Assay Development Program (CADP), National Cancer Institute, NIH, 6130 Executive Boulevard, EPN/6042, Bethesda, MD 20892, 301–496–1591, livelyt@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, VerDate Mar<15>2010 14:47 Oct 26, 2011 Jkt 226001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the meeting of the National Cancer Advisory Board. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. A portion of the meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Advisory Board, Subcommittee on Global Cancer Research. Open: December 5, 2011, 6:30 p.m. to 8 p.m. Agenda: Discussion on Global Cancer. Place: Hyatt Regency Bethesda, One Metro Center, Bethesda, MD 20814. Contact Person: Dr. Ted Trimble, Executive Secretary, NCAB Subcommittee on Global Cancer Research, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, EPN/7025, Rockville, MD 20892– 8345, (301) 496–2522, trimblet@mail.nih.gov. Name of Committee: National Cancer Advisory Board. Open: December 6, 2011, 9 a.m. to 3:30 p.m. Agenda: Program reports and presentations; business of the Board. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 66733 Closed: December 6, 2011, 3:30 p.m. to 5 p.m. Agenda: Review intramural program site visit outcomes. Discussion of confidential personnel issues. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892–8327, (301) 496–5147. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: deainfo.nci.nih.gov/advisory/ncab.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: October 21, 2011 Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–27865 Filed 10–26–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c) (4) and 552b(c) (6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical E:\FR\FM\27OCN1.SGM 27OCN1

Agencies

[Federal Register Volume 76, Number 208 (Thursday, October 27, 2011)]
[Notices]
[Page 66733]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-27867]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2) notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c) (4) and 552b(c) (6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources, biologics, clinical assays and 
other developmental programs for potential new therapeutics for the 
treatment of cancer. The outcome of the evaluation will provide 
information to internal NCI committees that will decide whether NCI 
should support requests and make available contract resources for 
development of the potential therapeutic to improve the treatment of 
various forms of cancer. The research proposals and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Clinical Assay Development Program (CADP).
    Date: November 29, 2011.
    Time: 8 a.m.-3 p.m.
    Agenda: To review grant applications for the CADP.
    Place: Bethesda Marriott North Hotel, 5701 Marinelli Road, 
Bethesda, MD 20852.
    Contact Person: Dr. Tracy Lively, Executive Secretary, Clinical 
Assay Development Program (CADP), National Cancer Institute, NIH, 
6130 Executive Boulevard, EPN/6042, Bethesda, MD 20892, 301-496-
1591, livelyt@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: October 21, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-27867 Filed 10-26-11; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.